Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Novartis Reports Positive Data On Psoriasis Drug Cosentyx - Analyst Blog - Yahoo Finance

National Psoriasis Foundation backs bill to lower treatment cost -- PORTLAND, Ore., March 26, 2015 /PRNewswire-USNewswire/ --

Approximately 995 patients, who achieved Psoriasis Area Severity Index (PASI) 75 response after a year of therapy (Week 52), received Cosentyx 300 mg, Cosentyx 150 mg or placebo for an additional year (Week 104). Results from the trials after two full years of therapy showed that 7 out of 10 (71%) patients treated with Cosentyx 300 mg had clear or almost clear skin (PASI 90); 4 out of 10 (44%) had clear skin (PASI 100) and almost 9 out of 10 (88%) patients maintained their PASI 75 response. Meanwhile, Novartis is also evaluating Cosentyx for the treatment of ankylosing spondylitis and psoriatic arthritis.
For the original version including any supplementary images psoriasis espanol or video, visit http://finance.yahoo.com/news/novartis-reports-positive-data-psoriasis-201408379.html

Study: Psoriasis Drug May Increase Shingles Risk; The Center for the Biology of Chronic Disease (CBCD) Reviews the Study

herpes remedy "Access to safe and effective treatments is the number one challenge for our community. PATA will lower out-of-pocket costs on needed medications so millions with psoriatic disease can better manage their condition." As part of the Coalition for Accessible Treatments a partnership of 32 patient and provider organizations http://psoriasisremedyguide.info/natural-remedy-psoriasis-hand/ that created the PATA legislation the National Psoriasis Foundation fights for fair and affordable access to treatments hiv and psoriasis for millions of Americans with psoriasis and psoriatic arthritis. These are serious, systemic autoimmune diseases with a profound physical, social, psychological and financial burden. Psoriasis, the most common autoimmune disease in the country, increases people's risk for heart disease, heart attack, stroke and early death. Treatment with systemic and biologic drugs can reduce a person's risk for these comorbidities. Additionally, treating psoriatic arthritis early and effectively can prevent irreversible joint damage.
For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/national-psoriasis-foundation-backs-bill-to-lower-treatment-cost-300056539.html

We urge the public to talk to their doctors about immune system damaging effects of any drugs they use. - Greg Bennett, CBCD Dr. Guy Shalom wrote that our study results might suggest the need for vaccination against VZV (varicella zoster virus). (1) The CBCD points out that Zostavax is an existing vaccine that was found to reduce the risk of developing a shingles outbreak in 60% of those vaccinated. The vaccine also decreases the long-term pain from post-herpetic neuralgia (PHN). In adults vaccinated at age 60 years or older, however, protection from the vaccine decreases within the first 5 years after vaccination. (See the CDC, Last Reviewed on May 1, 2014) (5) The CBCD recommends that individuals who have ever had chickenpox take Novirin.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/03/prweb12605012.htm

Don't be the product, buy the product!